- Home
- SABA vs SGMT Comparison
SABA vs SGMT Comparison
Compare SABA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABA
- SGMT
- Stock Information
- Founded
- SABA 1988
- SGMT 2006
- Country
- SABA United States
- SGMT United States
- Employees
- SABA N/A
- SGMT N/A
- Industry
- SABA
- SGMT
- Sector
- SABA
- SGMT
- Exchange
- SABA Nasdaq
- SGMT Nasdaq
- Market Cap
- SABA 254.3M
- SGMT 269.2M
- IPO Year
- SABA N/A
- SGMT 2023
- Fundamental
- Price
- SABA $9.40
- SGMT $8.96
- Analyst Decision
- SABA
- SGMT Strong Buy
- Analyst Count
- SABA 0
- SGMT 6
- Target Price
- SABA N/A
- SGMT $26.83
- AVG Volume (30 Days)
- SABA 290.0K
- SGMT 801.8K
- Earning Date
- SABA 01-01-0001
- SGMT 08-13-2025
- Dividend Yield
- SABA 12.91%
- SGMT N/A
- EPS Growth
- SABA N/A
- SGMT N/A
- EPS
- SABA N/A
- SGMT N/A
- Revenue
- SABA N/A
- SGMT N/A
- Revenue This Year
- SABA N/A
- SGMT N/A
- Revenue Next Year
- SABA N/A
- SGMT N/A
- P/E Ratio
- SABA N/A
- SGMT N/A
- Revenue Growth
- SABA N/A
- SGMT N/A
- 52 Week Low
- SABA $3.64
- SGMT $1.73
- 52 Week High
- SABA $4.42
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- SABA 59.88
- SGMT 51.98
- Support Level
- SABA $9.17
- SGMT $7.98
- Resistance Level
- SABA $9.37
- SGMT $11.41
- Average True Range (ATR)
- SABA 0.13
- SGMT 0.84
- MACD
- SABA 0.00
- SGMT -0.26
- Stochastic Oscillator
- SABA 86.11
- SGMT 28.57
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.